Compare Chipotle Mexican Grill, Inc. (CMG) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Heron Therapeutics Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $36.29 (market cap $46.73B), while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 566.3× Heron Therapeutics Inc's market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CMG | HRTX | |
|---|---|---|
Market Cap | $46.73B | $82.52M |
Sector | Consumer Cyclical | Health |
52-Week High | $53.95 | $2.04 |
52-Week Low | $28.17 | $0.39 |
Enterprise Value | $51.11B | $180.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $36.63, up 3.91% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $36 and resistance at $37-38. Recent earnings beats and international expansion into Mexico highlight growth potential, though valuation remains elevated with a P/E of 33.61. Analyst consensus is strongly bullish with 70% buy ratings and a $40.43 price target.
CMG offers growth exposure through international expansion and operational excellence, but faces risks from premium valuation and margin pressures. Revenue growth has slowed to 5.3% in 2025 from 15.1% in 2023, while net margins declined to 12.87%. The stock's premium multiple requires sustained execution to justify current levels amid competitive and inflationary pressures.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
